Analysts Set ImmunityBio, Inc. (NASDAQ:IBRX) PT at $14.40

ImmunityBio, Inc. (NASDAQ:IBRX) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $14.40.

Several analysts have issued reports on IBRX shares. BTIG Research assumed coverage on shares of ImmunityBio in a research note on Thursday, March 12th. They set a “buy” rating and a $13.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. HC Wainwright upped their price target on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Finally, D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research note on Monday.

ImmunityBio Price Performance

Shares of IBRX opened at $7.41 on Friday. The company has a 50-day moving average of $7.47 and a two-hundred day moving average of $4.14. The stock has a market cap of $7.62 billion, a price-to-earnings ratio of -19.50 and a beta of -0.03. ImmunityBio has a one year low of $1.83 and a one year high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. Analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current year.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: China/Macau regulatory nod and wider market access for ANKTIVA supports longer‑term revenue opportunity and helped push the stock higher before the regulatory hit. Read More.
• Positive Sentiment: NCCN guideline update expanded clinical practice recognition for ANKTIVA in certain NMIBC patients, a credibility and commercialization catalyst cited by commentators as a driver of prior gains. Read More.
• Positive Sentiment: Sell‑side/support commentary and a high price target (D. Boral Capital reaffirmed a buy with a $23 target) had been supporting sentiment ahead of today’s move. Read More.
• Neutral Sentiment: Reported short‑interest entries over the last 24 hours show anomalous/zero values across multiple feeds; the data appears inconsistent and is unlikely to explain the intraday volume spike on its own. (Multiple short‑interest feeds reported 0 shares / 0.0 days-to-cover.)
• Negative Sentiment: Major near‑term negative catalyst — the FDA issued a warning letter saying a television ad and a podcast promoting ANKTIVA contained “false or misleading” claims and violated federal law; that regulatory action triggered heavy selling and broad coverage of the compliance risk. Read More.
• Negative Sentiment: Investor legal risk — a plaintiff‑side firm (Johnson Fistel) is investigating potential claims against ImmunityBio executives, increasing the risk of litigation or disclosure that could pressure the stock further. Read More.
• Negative Sentiment: Market commentary and trade publications are framing the FDA letter as the primary driver of today’s selloff and questioning management promotional practices; expect continued volatility and headlines while regulators and lawyers assess next steps. Read More.

Insider Transactions at ImmunityBio

In related news, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 501,967 shares of company stock worth $4,466,412 in the last quarter. 69.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently modified their holdings of IBRX. Slow Capital Inc. purchased a new stake in shares of ImmunityBio during the third quarter worth $25,000. Envision Financial Planning LLC purchased a new stake in shares of ImmunityBio during the 2nd quarter worth about $28,000. Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio during the 2nd quarter valued at about $27,000. Truist Financial Corp acquired a new stake in shares of ImmunityBio during the 3rd quarter valued at about $27,000. Finally, Swiss Life Asset Management Ltd bought a new stake in shares of ImmunityBio in the 3rd quarter valued at approximately $27,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.